The healthcare industry is undergoing a significant digital transformation driven by the need for more personalized, accessible, and effective treatment options. At the forefront of this revolution is Digital Therapeutics (DTx), a new class of evidence-based, software-driven therapeutic interventions that harness the power of digital technology to prevent, manage, and treat medical conditions. Unlike traditional treatments, DTx solutions are designed to be seamlessly integrated into a patient’s daily life, offering personalization and engagement that conventional therapies often lack. 

Digital Therapeutics

Digital therapeutics encompass a range of applications, ranging from managing chronic diseases, including diabetes and cardiovascular conditions, to treating mental health disorders and substance abuse. These solutions are grounded in clinical evidence, ensuring their efficacy and safety are comparable to, or even exceed traditional pharmaceutical interventions. As the adoption of DTx continues to grow, it is poised to redefine the standards of care across various therapeutic areas, driving better patient outcomes and reducing healthcare costs.  

This article explores the landscape of Digital Therapeutics, examining the underlying technology, key players in the market, regulatory challenges, and the potential impact on the future of healthcare. By delving into the benefits, limitations, and real-world applications of DTx, we aim to provide a comprehensive understanding of how this innovative technology is reshaping the treatment paradigm.  

Key Technologies in DTx (Digital Therapeutics)

• Mobile Applications and Gamification  

Mobile applications and gamification are transforming Digital Therapeutics (DTx) by enhancing patient engagement and adherence through interactive, personalized interventions. These technologies leverage AI and real-time feedback, integrating with health data from wearables and Electronic Health Records (EHRs).   

Notable examples include Akili Interactive’s EndeavorRx, an FDA-approved digital therapeutic for ADHD that uses gamification to improve cognitive function, and Omada’s Health Platform, which combines mobile app-based interventions with GLP medications for chronic diseases like diabetes and obesity. Additionally, Welldoc's BlueStar® integrates with a smartphone application to provide real-time glucose monitoring and personalized feedback.  

Pharmaceutical companies are increasingly partnering with DTx firms to blend therapeutic expertise with digital innovation, optimizing patient outcomes across mental health and chronic conditions while maintaining a competitive edge.  

• Wearables and Sensors  

Wearables and sensors are revolutionizing Digital Therapeutics (DTx) by providing continuous, real-time health monitoring and enhancing chronic condition management. These devices, such as Fitbit and Garmin wearables, track metrics like heart rate and physical activity, offering actionable insights to refine treatment plans.   

For instance, Propeller Health’s smart inhalers track medication use and symptoms to improve asthma and COPD management. Additionally, Livongo’s platform uses connected devices to monitor diabetes, providing personalized feedback through integration with remote monitoring tools. The integration of wearables into DTx strategies enables pharmaceutical companies to combine these technologies with traditional therapies, leading to improved patient adherence and treatment outcomes.  

Read more: Winning in Implantable Medical Devices Market: Pharma’s Next Frontier 

• Artificial Intelligence, Machine Learning, and Natural Language Processing  

AI, ML, and NLP are pivotal in digital health therapeutics, enhancing the personalization and effectiveness of treatments. AI and ML analyze patient data to predict outcomes and tailor interventions, while NLP improves interactions through chatbots and virtual assistants.   

Examples include Biofourmis’ BioVitalsHF, which uses ML to anticipate heart failure exacerbations, and Woebot Health’s WB001, a natural language processing-based chatbot designed to support postpartum depression (PPD) through cognitive behavioral therapy. These technologies are integrated into healthcare systems to drive more effective and responsive digital therapeutic solutions.  

• Telehealth and Remote Monitoring  

Telehealth and remote monitoring are critical to modern digital therapeutics, enabling continuous patient engagement and tailored care. They allow for real-time monitoring and adjustments of treatment plans, especially for chronic conditions.   

For example, Omada Health offers digital programs for diabetes and hypertension that utilize remote monitoring to track and adjust patient progress. Propeller Health’s digital therapeutic integrates remote inhaler monitoring with telehealth support to optimize asthma and COPD care. Similarly, Livongo combines connected devices with telehealth consultations to manage diabetes. The industry is trending towards hybrid models that merge telehealth, remote monitoring, and digital therapeutics, providing a comprehensive approach to personalized patient care.   

• Cloud Computing, Blockchain, and Big Data  

Cloud computing, blockchain, and big data play crucial roles in the advancement of digital therapeutics, enhancing data management, security, and personalization. Cloud computing provides scalable storage and processing, which is essential for managing extensive patient data, as seen with Omada Health’s platforms.   

Blockchain technology helps ensure data integrity and security through decentralized ledgers, with companies like Guardtime applying it to secure data sharing and maintain tamper-proof records. Big data analytics supports the aggregation and analysis of large datasets, allowing for the optimization of digital therapeutics, such as Akili Interactive’s EndeavorRx, by refining treatment based on comprehensive user data. Together, these technologies underpin the development of scalable, secure, and effective digital therapeutic solutions.  

Read more: Sustainability Efforts by the Pharmaceutical Industry 

Market Map and Key DTx Players   

Diabetes --Pioneers/Disruptors  

• Better Therapeutics’ AspyreRx is the first FDA-authorized cognitive behavioral therapy (CBT) app to treat adults with type 2 diabetes (T2D). It was acquired by Click Therapeutics, a med tech company.   
• One of the disruptors of DTx in the USA, One Drop, uses tools to manage diabetes and aids people in managing their condition collectively. 
• Livongo Health and Voluntis partnered to offer the Livongo for Diabetes program with Voluntis' Insulia®, an FDA-cleared medical device and app that provides basal insulin dose recommendations for Type 2 diabetes patients. 

Cardiovascular       

• Lupin Digital Health’s (subsidiary of Lupin) digital therapeutics solution, LYFE, is India’s only evidence-based holistic heart care program that reduces the risk of a heart attack and improves vitals as well as the quality of life for cardiac patients.  

Sleep Disorder  

• Somryst is a prescription-only digital therapeutic intended to provide a neurobehavioral intervention (Cognitive Behavioral Therapy for Insomnia — CBT-I) to patients with chronic insomnia. Impact: 45% reduction in the severity of insomnia symptoms. 
• A digital sleep improvement program, Sleepio, is accessible on mobile and the web. It is clinically proven to help clear your mind and improve your sleep. Impact: helped 76% of patients achieve clinical improvement in insomnia.  

Other Key Players   

• ResMed acquired Mementor, a consumer software developer that offers Somnio – a digital solution for insomnia.   

Substance Abuse  

• Pretaa, a US-based behavioral analytics company, has partnered with Fitbit Health Solutions to improve outcomes for Americans affected by substance abuse by incorporating Fitbit’s devices and services into Pretaa’s substance abuse recovery offering.  
• Pear Therapeutics partnered with Sandoz, a Novartis division, for its reSET-O product for patients with Substance Use Disorder (SUD). It became the first FDA-cleared prescription digital therapeutic for the treatment of opioid use disorder.   

Mental/Behavioral Health    

• One of the digital therapeutic companies, Lark Health, is a platform for managing behavioral health using AI.   
• A pediatric behavioral health firm, Cognoa, has a Canvas Dx platform for earlier and equitable diagnosis and treatment of behavioral health issues.  

Challenges in Digital Therapeutics: Why Funding is Declining Despite Potential? 

The decline in funding for digital therapeutics (DTx) is significant despite their considerable potential. In Q1’23, the digital and wellness technology sector experienced its lowest funding levels since Q4’2019, marking a QoQ decline of 23%. This reduction reflects several key challenges: fragmented reimbursement systems and the lack of standardized coding complicate financial viability while securing reimbursement requires robust and resource-intensive clinical and economic evidence.  

Several companies in the digital therapeutics (DTx) space are facing significant financial hurdles due to reimbursement challenges. Notably, Pear Therapeutics, despite having FDA-approved products, has declared bankruptcy. This underscores the difficulties that even well-regarded DTx companies can encounter in securing adequate reimbursement and achieving financial sustainability. 

Regulatory hurdles further contribute to the decline, as companies must navigate complex and evolving regulations across various regions. Additionally, the competitive landscape and some high-profile failures have dampened investor confidence. Consequently, despite promising advancements, these challenges have led to a cautious funding environment, underscoring the need for improved reimbursement models, regulatory clarity, and demonstrated value to stakeholders. These issues foster an environment that could support more efficient and widespread adoption of digital therapeutics. 

Read more: The New Frontier – Intersection of Healthcare & Gen AI 

Table 1: Summary of the reimbursement challenges for digital therapeutics (DTx) in key markets and the initiatives taken by governments to address these challenges.

Source: Springer Nature, European Federation of Pharmaceutical Industries and Associations (EFPIA), Digital Therapeutics Alliance and SGA Analysis 

Pharma and DTx Companies: Key Considerations and Recommendations  

The rapid evolution of Digital Therapeutics (DTx) is reshaping the healthcare industry by delivering personalized, evidence-based solutions that integrate smoothly into patients' daily lives. While this advancement helps in enhancing patient outcomes, it also challenges traditional pharmaceutical models. For pharmaceutical and DTx companies to thrive in this dynamic environment, they need to adopt a strategic approach. Here are key recommendations:  

• Integrate Digital and Traditional Therapies 

Companies should aim to blend DTx with conventional pharmaceutical treatments to create comprehensive care plans. This integration ensures that digital solutions complement existing therapies, thereby boosting patient adherence and improving outcomes.  

• Navigate Regulatory Challenges 

As the regulatory framework for DTx continues to evolve, proactive engagement with regulatory bodies is essential. Developing clear approval and reimbursement pathways will be crucial for efficiently bringing DTx products to market.  

Read more: Data and Analytics in Healthcare: Benefits and its Importance 

• Ensure Data Security and Patient Privacy 

Given the reliance on patient data, implementing robust security and privacy measures is critical. Companies should consider advanced technologies like blockchain to safeguard patient information and maintain trust.  

• Demonstrate Clinical and Economic Value  

To attract funding and gain payer acceptance, DTx companies must produce compelling clinical and economic evidence. This involves conducting thorough clinical trials and real-world studies to validate the effectiveness and cost-efficiency of their products.  

Addressing these key areas will enable pharmaceutical and DTx companies to leverage the growing potential of digital therapeutics while navigating the challenges of this rapidly evolving field. 

About SG Analytics   

SG Analytics (SGA) is an industry-leading global data solutions firm providing data-centric research and contextual analytics services to its clients, including Fortune 500 companies across BFSI, Technology, Media & Entertainment, and Healthcare sectors. Established in 2007, SG Analytics is a Great Place to Work® (GPTW) certified company with a team of over 1200 employees and a presence across the U.S.A., the UK, Switzerland, Poland, and India.     

A leader in the healthcare domain, SG Analytics assists healthcare companies in leveraging the power of information. Contact us today if you are in search of efficient Healthcare solutions to make sound business decisions.     

Apart from being recognized by reputed firms such as Gartner, Everest Group, and ISG, SGA has been featured in the elite Deloitte Technology Fast 50 India 2023 and APAC 2024 High Growth Companies by the Financial Times & Statista.